

This is a repository copy of *Treatment and rehabilitation of Long COVID:A scope of the literature. Update July 2024.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/217160/>

Version: Published Version

Monograph:

Raine, Gary Austin, Khouja, Claire Louise orcid.org/0000-0002-9571-3147, Fulbright, Helen et al. (2 more authors) (2024) Treatment and rehabilitation of Long COVID:A scope of the literature. Update July 2024. Research Report. EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London. , London.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Treatment and rehabilitation of Long COVID

A scope of the literature: update

July 2024

The NIHR Policy Research Programme Reviews Facility is a collaboration
between the following:

Treatment and rehabilitation of Long COVID: A scope of the literature. Update July 2024

Raine G, Khouja C, Fulbright H, Sutcliffe K, Sowden A

July 2024

Raine G, Khouja C, Fulbright H, Sutcliffe K, Sowden A (2024) Treatment and rehabilitation of Long COVID: A scope of the literature. Update July 2024. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London.

Funding

This review was commissioned by the National Institute for Health Research (NIHR) Policy Research Programme (PRP) for the Department of Health and Social Care (DHSC). It was funded through the NIHR PRP contract with the EPPI Centre at UCL (Reviews facility to support national policy development and implementation, NIHR200701). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the DHSC.

Conflicts of interest

There were no conflicts of interest in the writing of this report.

Contributions

The opinions expressed in this publication are not necessarily those of the EPPI Centre or the funders. Responsibility for the views expressed remains solely with the authors.

This report should be cited as:

Raine G, Khouja C, Fulbright H, Sutcliffe K, Sowden A (2024) *Treatment and rehabilitation of Long COVID: A scope of the literature. Update July 2024*. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London.

Editorial & design by: Lionel Openshaw

ISBN: 978-1-911605-61-4

© Copyright 2024

Authors of the systematic reviews on the EPPI Centre website (<http://eppi.ioe.ac.uk/>) hold the copyright for the text of their reviews. The EPPI Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data-extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided. Otherwise, users are not permitted to duplicate, reproduce, re-publish, distribute, or store material from this website without express written permission.

Summary

- We identified 19 randomised controlled trials published between March and June 2024 that were focused on Long COVID treatment or rehabilitation. Across our nine reports produced to date, we have identified and assessed 140 trials published between January 2022 and June 2024.
- Eight of the 19 trials focused on treating generalised or multiple symptoms of Long COVID. Four trials focused specifically on respiratory or cardiovascular function or physical fitness. Four other trials focused solely on treating persistent problems with the sense of smell or taste (olfactory/gustatory dysfunction) and three trials evaluated treatments for fatigue.
- Two trials were rated positively for 10 out of the 13 quality criteria that we assessed. The other 17 trials gained a positive rating for between four and nine criteria.

Introduction

This is the ninth report in an ongoing series of quarterly evidence scans requested by NHS England and the Department of Health and Social Care. It was conducted to identify and quality assess randomised controlled trials (RCTs) evaluating treatment or rehabilitation for Long COVID published in the three-month period between March and June 2024.

Method

Identification of studies

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) using a range of key terms that have been used in the literature to describe symptoms and effects persisting beyond the acute stage of COVID-19 infection. Searches of MEDLINE, Embase, PsycINFO and CINAHL were also conducted to identify any trials that had not been incorporated into CENTRAL. We translated the CENTRAL search strategy for use in each database and used study design search filters to restrict retrieval to randomised controlled trials.

Searches were limited to studies added to the databases or published between 2022 and 2024, and no language restrictions were applied. Preprints were removed from the searches in MEDLINE and Embase. Due to the rapid nature of the project, the database searches were designed to balance the need to retrieve as many relevant trials as possible against the limited time available for screening. Records were downloaded into EndNote and deduplicated against the search results from previous updates. Full search strategies can be found in Appendix 1 (page 18).

Study selection

Studies were screened for inclusion against the following criteria:

Population - patients with Long COVID, which we conceptualised broadly as experiencing at least one symptom or effect that persists or develops after acute COVID-19 infection. No restrictions were placed on the socio-demographic characteristics of participants or COVID severity. We also did not apply criteria relating to the time period after acute infection owing to variation in how Long COVID has been defined in the literature.

Interventions - any intervention aimed at treating or rehabilitating patients with Long COVID. This could include, but was not limited to, medication, supplements, and physical therapy.

Interventions that had a primary focus on general rehabilitation from COVID-19 following hospitalisation or severe infection were excluded.

Outcomes - any outcome related to the effectiveness, cost-effectiveness, safety or side effects of interventions. Studies could also report outcomes related to the implementation of interventions.

Study design - prospective trials with random allocation of participants to intervention and comparator groups. When designed and conducted to a high standard, a randomised controlled trial is often the most robust type of primary study design for investigating intervention effectiveness.⁽¹⁾

Publication type and status - any publication type, except pre-prints and conference abstracts, which reports findings from a RCT (e.g., full papers, research letters, brief reports etc).

Quality assessment

Each study was appraised according to the Joanna Briggs Institute (JBI) Checklist for Randomized Controlled Trials.⁽²⁾ In contrast to the Cochrane Risk of Bias Tool,⁽³⁾ the JBI checklist does not require an assessment of bias for specific outcomes. It provides instead a general appraisal of each trial as a whole, which was needed in this piece of work as we were not seeking to extract and synthesise outcome data. Assessments were conducted by one reviewer and checked by another. The appraisal identified potential sources of bias and threats to the validity and reliability of study findings. The full checklist is provided in Appendix 2 (page 26).

Key findings

We screened 345 records and included 19 RCTs that had been published since March 2024.⁽⁴⁻²²⁾ We included a similar number of trials in three of our previous eight reports: January 2024 (n=21);⁽²³⁾ July 2023 (n=18);⁽²⁴⁾ and April 2023 (n=18).⁽²⁵⁾ The number of trials included in our other five reports was: April 2024 (n=15);⁽²⁶⁾ October 2023 (n=12);⁽²⁷⁾ January 2023 (n=12);⁽²⁸⁾ October 2022 (n=11)⁽²⁹⁾ and July 2022 (n=14).⁽³⁰⁾ The flow of studies through the current update is shown in Appendix 3 (page 27). Table 1 (page 6) presents the aim(s) and key characteristics of the 19 trials.

Interventions

Eight trials focused on individuals experiencing generalised or multiple symptoms of Long COVID.^(4, 9, 11-14, 17, 22) Five of the eight trials evaluated physical rehabilitation programmes. Of these, two evaluated multicomponent cardiopulmonary rehabilitation programmes comprising activities such as aerobic exercise, respiratory muscle training, and resistance training.^(9, 11) One trial assessed inspiratory muscle training combined with aerobic exercise and neurorehabilitation (olfactory and gustatory training) for individuals experiencing both persistent dyspnoea and loss of their sense of smell or taste.⁽¹⁷⁾ One trial evaluated resistance training for treating older adults (65 years old and over).⁽¹³⁾ Another trial compared the effects of virtual reality-simulated treadmill exercise and conventional treadmill exercise.⁽⁴⁾

Of the remaining three trials focused on people with generalised or multiple symptoms of Long COVID, one evaluated a psychological programme (PsiCoRes) based on third-generation therapies (elements of Acceptance and Commitment Therapy and mindfulness).⁽¹²⁾ One trial investigated biosound therapy, which comprised biofeedback, vibroacoustic therapy synchronised with binaural beats, and video content.⁽¹⁴⁾ The third trial evaluated the

consumption of hydrogen-rich water on individuals with both persistent fatigue and dyspnoea.⁽²²⁾

Four trials assessed treatments for individuals who primarily had problems with respiratory or cardiovascular function or physical fitness.^(10, 16, 18, 21) Three of the four trials focused on assessing the effectiveness of exercise-based rehabilitation programmes and/or inspiratory muscle training;^(10, 16, 21) The fourth trial focused primarily on the feasibility and safety of a virtual pulmonary rehabilitation programme delivered through group or self-directed sessions, and participants' satisfaction with the programme; several effectiveness measures were assessed as secondary outcomes.⁽¹⁸⁾

Four trials focused solely on persistent problems with the sense of smell or taste and investigated various potential treatments: topical platelet-rich plasma;⁽⁸⁾ frequency-controlled ear acupuncture;⁽¹⁵⁾ topical nasal corticosteroid (mometasone furoate monohydrate) and olfactory training (OT);⁽¹⁹⁾ and ultramicrosized palmitoylethanolamide and luteolin (umPEALUT) with OT; alpha-lipoic acid with OT; and combined therapy (umPEALUT, alpha-lipoic acid and OT).⁽⁶⁾

Three trials focused on treatments primarily for fatigue. One assessed RSLV-132 (a catalytically active RNase Fc fusion protein)⁽⁵⁾ and another evaluated an asynchronous multimodal telerehabilitation programme.⁽⁷⁾ The third trial investigated the effects of creatine supplementation with or without glucose and required participants to have fatigue plus one other persistent COVID symptom.⁽²⁰⁾

Approximately half of the trials included in both the current update (10 out of 19 RCTs) and our previous report in April 2024 (7 out of 15 RCTs)⁽²⁶⁾ evaluated interventions incorporating an exercise component and/or breathing training. None of our other seven reports included a larger proportion. As detailed previously, four out of the 19 trials in the current update had a focus on treating olfactory/gustatory dysfunction. This proportion is larger than we included in our April report (two out of 15 RCTs)⁽²⁶⁾ and is similar to the proportion included in our January 2024 report (4 out of 19 RCTs).⁽²³⁾ Four out of our other six reports all included a larger proportion of trials addressing olfactory/gustatory dysfunction.^(24, 25, 27, 29)

Participants

Eight trials recruited participants who had experienced persistent effects, on average, for at least four weeks after the onset of COVID symptoms or diagnosis.^(5, 8, 10, 13-15, 17, 22) In five of the eight trials, participants had persistent effects for at least 12 weeks after symptom onset or diagnosis.^(5, 8, 10, 13, 17)

Participants in two trials reported persistent symptoms at least three months after infection⁽¹⁸⁾ or, on average, five months (4–40 weeks) before study recruitment.⁽¹⁹⁾ In another trial, participants reported persistent symptoms after having COVID in the previous three to four months.⁽⁴⁾

Three trials recruited individuals at least four weeks;⁽⁹⁾ three to 24 months;⁽⁶⁾ and approximately two years (median 31 months) after recovery or hospital discharge.⁽²¹⁾ In one trial, recruitment occurred within the first two weeks after discharge.⁽⁷⁾ Participants in another trial were recruited whilst in hospital and had an initial assessment two days prior to discharge. On average, these participants had been hospitalised for 80 days.⁽¹⁶⁾ The remaining three trials recruited individuals with persistent symptoms, but no time-related details were reported.^(11, 12, 20)

Countries

Three trials were conducted in Spain^(7, 12, 17) and the USA.^(5, 8, 14) Two trials were conducted in Canada;^(10, 18) Egypt;^(4, 9) Germany;^(19, 21) and Italy.^(6, 16) One trial was conducted in Brazil;⁽¹¹⁾ China;⁽²²⁾ Iran;⁽¹⁵⁾ Poland;⁽¹³⁾ and Serbia.⁽²⁰⁾

Trial quality

Assessments of the trials against the JBI criteria are provided in Table 2 (page 13). None of the trials were assessed as having a low risk of bias for more than ten of the 13 appraisal criteria. Two trials met ten criteria^(15, 17) and 17 were rated positively for between four and nine criteria.^(4-14, 16, 18-22)

A number of common issues were identified across the 19 trials. For example, in 13 trials, we could not tell if an appropriate procedure had been used to prevent researchers from knowing whether the next patient would be allocated to the treatment or comparator group (allocation concealment) (Q2).^(5, 7, 8, 10, 12-16, 18, 20-22) In another trial,⁽¹⁹⁾ participants were assigned to groups on an alternating basis and consequently we could not give this study a positive rating for allocation concealment.

An Intention to treat (ITT) analysis was not conducted in 12 trials (Q9)^(4-6, 8-11, 13, 14, 16-18) and in another study, we could not tell if it had been used.⁽¹²⁾ It was unclear if an appropriate statistical analysis had been conducted in ten trials as no information was provided about the sample size requirements of the study (Q12).^(4-7, 10, 14, 18-20, 22)

In four trials that we rated positively for nine^(7, 9, 11) or ten⁽¹⁷⁾ of the 13 criteria, there was no blinding of trial participants (Q4) and the personnel who administered the treatment (Q5). However, the nature of the intervention in these trials is likely to have precluded the use of blinding as all four evaluated rehabilitation programmes. In one of the four trials, we were unable to tell if the outcome assessors were blinded.⁽⁹⁾

It was unclear whether trial participants were blinded in two of the remaining 15 trials (Q4).^(6, 21) In ten of the 15 trials, we also could not tell if there was blinding of the personnel who administered the treatment (Q5)^(6, 20) and/or the outcome assessors (Q6).^(5, 12, 13, 15, 16, 18-21) In six of the 15 trials, there was no blinding of participants (Q4) and the personnel who administered the treatment (Q5).^(10, 12, 13, 16, 18, 19) In two trials, there was no blinding of the personnel who administered the treatment (Q5).^(15, 21) Neither the personnel who administered the treatment nor those who assessed outcomes were blinded in two trials.^(8, 22) There was no blinding of trial participants, the personnel who administered the treatment nor outcome assessors in two other trials.^(4, 14) The nature of the intervention in some of these 15 trials may have prevented the blinding of participants and/or study personnel.

Conclusion

To conclude, in this evidence scan, we identified 19 RCTs published between March and June 2024 that examined interventions for the treatment or rehabilitation of people with Long COVID. Across our nine reports produced to date, we have identified and assessed 140 trials published since January 2022. Eight trials in the current update focused on treating generalised or multiple symptoms of Long COVID. Eight other trials focused specifically on cardiovascular function/physical fitness (n=4) or olfactory/gustatory dysfunction (n=4). Three trials evaluated treatments for fatigue (n=3). All trials were rated positively for between four and ten of the 13 quality criteria we assessed.

Table 1: Study characteristics (n=19)

First author (year) Country	Aim of study	Main symptom or effect experienced	Post COVID time	Participants' gender (n) and % female	Primary outcome(s) of interest	Comparator
Ahmad (2024) ⁽⁴⁾ Egypt	To assess the effects of traditional treadmill exercise compared to virtual reality-simulated treadmill exercise on fatigue, cognitive function, sleep quality, and participant satisfaction with the exercise programme in post-COVID-19 subjects	General/multiple: persistent dyspnoea and fatigue, oxygen saturation $\geq 94\%$, and mild cognitive impairment	Unclear/not stated: a history of COVID-19 infection within three to four months	Mixed (20; 16 analysed) 85% female (17/20)	Fatigue: Chalder Fatigue Scale Cognitive: Montreal Cognitive assessment (MoCA) Psychological: Pittsburgh Sleep quality index (PSQI)	Traditional treadmill exercise programme, without the virtual reality
Andrews (2024) ⁽⁵⁾ USA	To assess whether intravenous doses of RSLV-132 would improve inflammation, neuroinflammation, and fatigue associated with post-acute sequelae of SARS-CoV-2 infection (PASC)	Fatigue/lack of energy	After diagnosis: 24 or more weeks after testing positive or diagnosis	Mixed (108; 95 analysed) 50% female (53/105)	Fatigue: PROMIS Fatigue SF 7a	Placebo
Cantone (2024) ⁽⁶⁾ Italy	To investigate whether treatment regimens involving ultramicroemulsions of palmitoylethanolamide and luteolin (umPEALUT), alpha-lipoic acid (ALA), or both, combined with olfactory training could ameliorate parosmia or quantitative	Olfactory and/or gustatory dysfunction	After recovery: 3-24 months from post-COVID negative nasopharyngeal swab to initial olfactory evaluation. Participants had	Mixed (120; 89 analysed) 57% female (51/89)	Olfactory and/or gustatory function: resolution of parosmia (parosmia questionnaire)	Olfactory training only

	smell dysfunction in patients with chronic olfactory dysfunction after SARS-CoV-2 infection		tried olfactory training and failed to improve			
Carpallo-Porcar (2024) ⁽⁷⁾ Spain	To preliminarily analyse whether a multimodal rehabilitation programme using asynchronous telerehabilitation in post-acute COVID-19 is as effective and feasible on fatigue, physical condition, and quality of life as traditional rehabilitation models	Fatigue/lack of energy	After discharge: within two weeks of discharge	Mixed (35; 27 completed) 57% female (20/35)	Fatigue: Fatigue Severity Scale (FSS)	The same multimodal exercise programme via a booklet only
Duffy (2024) ⁽⁸⁾ USA	To investigate the use of topical platelet-rich plasma for the treatment of post-COVID-19 olfactory dysfunction	Olfactory and/or gustatory dysfunction	After diagnosis: positive test and six months or more of symptoms	Mixed (85; 83 analysed) 71% female (59/83)	Olfactory and/or gustatory function: Brief Smell Identification Test (BSIT)	Placebo: saline impregnated Surgifoam treatment
Elyazed (2024) ⁽⁹⁾ Egypt	To investigate the effect of home-based pulmonary rehabilitation on exercise capacity in patients with post COVID-19 syndrome	General/multiple: post-COVID syndrome, and fatigue, dyspnoea, and exercise intolerance	After recovery: at least one month after acute phase recovery	Mixed (68; 60 analysed) 45% female (27/60)	Pulmonary/respiratory or cardiovascular function: Modified Medical Research Council (mMRC) scale Physical fitness: Six-Minute Walk Test (6MWT); Harvard Step Test (Physical Fitness Index, PFI)	Usual medical care

					Quality of life: Short Form 36 (SF-36) Fatigue: Chalder Fatigue Scale	
Gaudreau-Majeau (2024) ⁽¹⁰⁾ Canada	To assess the effectiveness of an eight-week cardiopulmonary rehabilitation programme on cognition, psychological well-being, and sleep quality in individuals with Long COVID-19	Respiratory or cardiovascular function or physical fitness: dyspnoea or asthenia (or a one-point increase in dyspnoea on the mMRC dyspnoea scale, compared with pre-COVID)	After diagnosis: three months after initial positive test	Mixed (40; 32 analysed) 66% female (25/38)	Psychological: Perceived-Stress Scale (PSS); Pittsburgh Sleep-Quality (PSQI); Geriatric Depression Scale (GDS); State-Trait Anxiety Inventory (STAI and TRAI) Cognitive: Montreal Cognitive Assessment (MoCA); Hopkins Verbal Learning Test (HVL); Digit Span, (a subtest of the Weschler Adult Intelligence Scale-IV); Trail Making Test, Mental Alternating Test; Verbal fluency tests	Usual activities (no change to diet or exercise)
Gomes dos Santos (2024) ⁽¹¹⁾ Brazil	To analyse the effects of cardiopulmonary rehabilitation (respiratory, aerobic, and resistance muscle training) on exercise tolerance, dyspnoea, fatigue, and body composition in individuals with post-COVID-19 syndrome	General/multiple: Post COVID syndrome - respiratory or functional symptoms including dyspnoea, cough and fatigue	Unclear/not stated: after acute infection, confirmed by PCR	Mixed (34; 33 analysed) 61% female (20/33)	Physical fitness: functional capacity (6MWT)	Biweekly remote health education lectures, delivered by a physical therapist; and maintain daily activities

Gonzalez-Moreno (2024) ⁽¹²⁾ Spain	To analyse the effectiveness of a psychological programme (PsiCoRes) based on third-generation therapies (mindfulness, and acceptance and commitment therapy) for improving psychological and emotional needs of patients with Long COVID	General/multiple: persistent COVID-19	Unclear/not stated: a diagnosis of persistent COVID-19	Mixed (70) 93% female (65/70)	Psychological: Subjective Happiness Scale (SHS); Self Compassion Scale (SCS); Perceived Stress Scale; State-Trait Anxiety Questionnaire; Beck Depression Inventory-II (BDI-II)	Waiting list
Kaczmarczyk (2024) ⁽¹³⁾ Poland	To develop and implement a specific and well-tolerated resistance exercise programme to reduce muscle weakness in older adults impacted by COVID-19	General/multiple: one or more post-COVID symptom (e.g., fatigue, muscle weakness, dizziness, headache, memory and concentration disorders, exercise intolerance or depression)	After diagnosis: positive test three to 12 months before the start of the study	Mixed (51; 46 analysed) 50% female (23/46)	Physical fitness: static and dynamic muscle strength; functional tests (timed up and go test, TUG; chair sit-to-stand tests, CS-30 and 5STS)	Usual activities
Korapatti (2024) ⁽¹⁴⁾ USA	To assess the impact of biosound therapy on Long COVID symptoms	General/multiple: at least three persistent COVID symptoms	After diagnosis: at least 30 days after positive COVID test	Mixed (14; 13 analysed) 77% female (10/13)	Psychological: Patient Health Questionnaire (PHQ-9); Generalized Anxiety Disorder (GAD-7) General or multiple: COVID-19 Persistent Symptom Questionnaire (developed by the study authors) Cognitive: Cambridge Brain Science (CBS) tasks; COVID-	Control group not described

					19 Persistent Symptom Questionnaire - memory	
Mohebbi (2024) ⁽¹⁵⁾ Iran	To investigate the efficacy of frequency-controlled ear acupuncture in treating COVID-19-related olfactory dysfunction	Olfactory and/or gustatory dysfunction	After diagnosis: 10 to 20 weeks of loss of smell after a positive test or close contact with a confirmed positive case	Mixed (40) 60% female (24/40)	Olfactory and/or gustatory function: Smell Identification Test	Sham treatment (laser switched off)
Paneroni (2024) ⁽¹⁶⁾ Italy	To evaluate the efficacy of home-based rehabilitation (aerobic reconditioning and muscle strengthening) with teleconsultations with a specialist nurse for patients with persistent effects following hospitalisation for COVID-19	Respiratory or cardiovascular function or physical fitness: persistent exercise intolerance or hypoxia at rest and/or during exercise (unable to walk predicted distance 6MWT; or on oxygen all day with a target of 94% or during exertion)	After discharge: first assessment was in the two days before hospital discharge. In-hospital stay averaged about 80 days	Mixed (79; 74 analysed; 55 at two-month follow-up) 28% female (22/79)	Physical fitness: effort tolerance (6MWT)	Remote teleconsultation with nursing staff
Sanchez (2024) ⁽¹⁷⁾ Spain	To test the efficacy of respiratory physiotherapy based on instrumental breathing training and aerobic exercise combined with olfactory and gustatory training in patients with Long COVID	General/multiple: symptoms of dyspnoea and loss or decrease of sense of smell or taste	After diagnosis: more than five months after symptom onset and diagnosis	Mixed (209; 200 analysed) 51% female (101/200)	Pulmonary/respiratory or cardiovascular function: spirometry - Forced Vital Capacity (FVC); maximum volume of exhaled air in the first second of the forced vital capacity (FEV1); FEV1/FVC ratio; Modified Borg Scale; mMRC dyspnoea scale	No treatment

					Olfactory and/or gustatory function: The Singapore Smell and Taste Questionnaire (SSTQ)	
Sarmiento (2024) ⁽¹⁸⁾ Canada	To assess the feasibility, safety, and satisfaction associated with an eight-week virtual pulmonary rehabilitation (PR) programme with the exercise component delivered through group or self-directed sessions	Respiratory or cardiovascular function or physical fitness: severe persistent respiratory symptoms	Unclear/not stated: three or more months after confirmed or suspected infection	Mixed (19; 14 analysed) 86% female (12/14)	Feasibility, tolerability and/or safety: feasibility, recruitment rate, completion rate, drop-out rate, safety, and satisfaction (Secondary outcomes: lung function, dyspnoea, fatigue, sit-to-stand capacity, and HRQoL)	Two intervention groups: 1) virtual PR program delivered in groups sessions via video conference by a physiotherapist 2) Self-directed exercise: the same PR programme performed unsupervised at home by following a pre-recorded video
Schmidt (2024) ⁽¹⁹⁾ Germany	To investigate topical nasal corticosteroid with olfactory training, versus olfactory training alone, for persistent olfactory dysfunction after a proven infection with SARS-CoV-2	Olfactory and/or gustatory dysfunction: loss of smell	Unclear/not stated: acute infection was on average 5 months (4–40 weeks) before recruitment	Mixed (20; 16 completed) 70% female (14/20)	Olfactory and/or gustatory function: Sniffin' Sticks; retro-nasal olfactory function test	Olfactory training only

Slankamenac (2024) ⁽²⁰⁾ Serbia	To investigate the effects of the administration of creatine for eight weeks, with or without glucose, on patient-reported outcomes, exercise tolerance, and tissue creatine levels in patients with Long COVID	Fatigue/lack of energy: moderate fatigue plus one other Long COVID symptom (ageusia, anosmia, body aches, breathing difficulties, difficulties concentrating, headache, lung pain, or general malaise)	Unclear/not stated: individuals with Long COVID symptoms	Mixed (15) 60% female (9/15)	Physical fitness: walking time to exhaustion Fatigue: Multidimensional Fatigue Inventory (MFI-20) test General or multiple: severity of Long COVID symptoms (visual analogue scale, VAS) Neurophysiological/brain imaging: concentrations of creatine assessed by magnetic resonance spectroscopy (MRS) in the vastus medialis muscle and thalamus, frontal, precentral, paracentral, and parietal white and grey matter of the brain	Glucose alone
Spiesshoefer (2024) ⁽²¹⁾ Germany	To investigate the impact of inspiratory muscle training on diaphragm and inspiratory muscle weakness and exertional dyspnoea in individuals with Long COVID	Respiratory or cardiovascular function or physical fitness: persistent diaphragm muscle weakness and associated dyspnoea	After discharge: approximately two years after discharge - median 31 months	Mixed (18; 18 analysed; 14 at six-week follow-up) 39% female (7/18)	Pulmonary/respiratory or cardiovascular function: change in inspiratory muscle fatiguability (time to task failure in seconds)	Sham inspiratory muscle training
Tan (2024) ⁽²²⁾ China	To investigate the impact of hydrogen-rich water (HRW) on the fatigue and dyspnoea of Long-COVID patients	General/multiple fatigue and dyspnoea	After diagnosis: Reported symptoms for more than four	Mixed (32) 69% female (22/32)	Pulmonary/respiratory or cardiovascular function: mMRC Dyspnoea Scale Physical fitness: 6MWT; 30-	Placebo water


			weeks after diagnosis		second Chair Stand Test (30s- CST) Fatigue: FSS	
--	--	--	--------------------------	--	---	--

Table 2: JBI risk of bias assessment

First author (year)	Q1. True randomisation?	Q2. Concealed allocation?	Q3. Similar at baseline?	Q4. Participants blind?	Q5. Treatment delivery blind?	Q6. Outcomes assessors blind?	Q7. Identical treatment?	Q8. Follow up complete?	Q9. ITT analysis?	Q10. Same outcome measurement?	Q11. Reliable measurement?	Q12. Appropriate statistical analysis?	Q13. Appropriate trial design?
Ahmad (2024)	+	+	+	-	-	-	+	-	-	+	+	?	+
Andrews (2024)	+	?	?	+	+	?	+	+	-	+	+	?	+
Cantone (2024)	+	+	?	?	?	+	+	-	-	+	+	?	+
Carpallo-Porcar (2024)	+	?	+	-	-	+	+	+	+	+	+	?	+
Duffy (2024)	?	?	+	+	-	-	+	+	-	+	+	+	+
Elyazed (2024)	+	+	+	-	-	?	+	+	-	+	+	+	+
Gaudreau-Majeau (2024)	+	?	-	-	-	+	+	+	-	+	+	?	+
Gomes dos Santos (2024)	+	+	?	-	-	+	+	+	-	+	+	+	+
Gonzalez-Moreno (2024)	+	?	?	-	-	?	+	?	?	+	+	+	+
Kaczmarczyk (2024)	+	?	-	-	-	?	+	+	-	+	+	+	+
Korapatti (2024)	?	?	?	-	-	-	+	+	-	+	+	?	?
Mohebbi (2024)	+	?	+	+	-	?	+	+	+	+	+	+	+
Paneroni (2024)	+	?	+	-	-	?	+	+	-	+	+	+	+
Sanchez (2024)	+	+	+	-	-	+	+	+	-	+	+	+	+
Sarmiento (2024)	+	?	?	-	-	?	+	+	-	+	+	?	+

Schmidt (2024)	?	-	+	-	-	?	+	+	+	+	+	?	+
Slankamenac (2024)	?	?	?	+	?	?	+	+	+	+	+	?	+
Spiesshoefer (2024)	?	?	+	?	-	?	+	+	+	+	+	+	+
Tan (2024)	+	?	+	+	-	-	+	+	+	+	+	?	+

+ = low risk of bias; ? = unclear risk of bias; - = high risk of bias



NB: figures may not add up to 100% due to rounding. In our reports, we adopt a 'once randomised, always analysed' approach to assessing the use of an ITT analysis (Q9), which is consistent with previous research and guidance.⁽³¹⁻³³⁾

References

1. Bhide A, Shah P, Acharya G. A simplified guide to randomized controlled trials. *Acta Obstetrica et Gynecologica Scandinavica*. 2018;97:380-7.
2. Joanna Briggs Institute. Checklist for Randomized Controlled Trials. The University of Adelaide, Adelaide: Joanna Briggs Institute; 2017. Available from: <https://jbi.global/critical-appraisal-tools>.
3. Sterne J, Savović J, Page M, Elbers R, Blencowe N, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366.
4. Ahmad AM, Mohamed Awad Allah SA, Abd E, G. A., Elsharawy DE, Ahmed HS, Mohamed Abdelwahab MA. Effects of conventional versus virtual reality-simulated treadmill exercise on fatigue, cognitive function, and participant satisfaction in post-COVID-19 subjects. A randomized trial. *Journal of Exercise Science & Fitness*. 2024;22(4):316-21.
5. Andrews JS, Boonyaratankornkit JB, Krusinska E, Allen S, Posada JA. Assessment of the impact of RNase in patients with severe fatigue related to Post-Acute Sequelae of SARS-CoV-2 infection (PASC): a randomized phase 2 trial of RSLV-132. *Clinical Infectious Diseases*. 2024;10.
6. Cantone E, D'Ascanio L, De Luca P, Roccamatysi D, La La Mantia I, Brenner MJ, et al. Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics. *European Archives of Oto-Rhino-Laryngology*. 2024;281(7):3671-8.
7. Carpallo-Porcar B, Calvo S, Alamillo-Salas J, Herrero P, Gomez-Barrera M, Jimenez-Sanchez C. An opportunity for management of fatigue, physical condition, and quality of life through asynchronous telerehabilitation in patients after acute Coronavirus Disease 2019: a randomized controlled pilot study. *Archives of Physical Medicine & Rehabilitation*. 2024.
8. Duffy A, Naimi B, Garvey E, Hunter S, Kumar A, Kahn C, et al. Topical platelet-rich plasma as a possible treatment for olfactory dysfunction-A randomized controlled trial. *International Forum of Allergy & Rhinology*. 2024.
9. Elyazed TIA, Alsharawy LA, Salem SE, Helmy NA, El-Hakim A. Effect of home-based pulmonary rehabilitation on exercise capacity in post COVID-19 patients: a randomized controlled trial. *Journal of Neuroengineering & Rehabilitation*. 2024;21(1):40.
10. Gaudreau-Majeau F, Gagnon C, Djedaa SC, Berube B, Malo J, Iglesias-Grau J, et al. Cardiopulmonary rehabilitation's influence on cognitive functions, psychological state, and sleep quality in long COVID-19 patients: A randomized controlled trial. *Neuropsychological Rehabilitation*. 2024:1-17.
11. Gomes dos Santos EG, Vieira da Costa K, Cordeiro de Souza IT, Victor dos Santos Felix J, Furtado B, C. B., de Souza Fernandes VM, et al. Effects of a cardiopulmonary rehabilitation protocol on functional capacity, dyspnea, fatigue, and body composition in individuals with post-COVID-19 syndrome: A randomized controlled trial. *Physiotherapy Research International*. 2024;29(2):e2086.
12. Gonzalez-Moreno J, Pozuelo C, Manos D, Gomez-Martinez S, Cantero-Garcia M. A third generation therapies approach in Long COVID patients: efficacy of an intervention program with Spanish adults. *Current Psychology*. 2024.

13. Kaczmarczyk K, Matharu Y, Bobowik P, Gajewski J, Maciejewska-Skrendo A, Kulig K. Resistance exercise program is feasible and effective in improving functional strength in Post-COVID survivors. *Journal of Clinical Medicine*. 2024;13(6).
14. Korapatti C, Vera L, Miller K. Biosound Therapy as a treatment for Long COVID patients: a pre-post pilot study. *Explore: The Journal of Science & Healing*. 2024;20(5):103000.
15. Mohebbi A, Bagheri SH, Raziabadi E, Shafiei A, Roomiani M, Arab M, et al. Effects of frequency-controlled ear acupuncture on COVID-19-related refractory olfactory dysfunction: a randomized clinical trial. *Jams Journal of Acupuncture & Meridian Studies*. 2024;17(2):69-75.
16. Paneroni M, Scalvini S, Perger E, Zampogna E, Govetto S, Oliva FM, et al. Home-based exercise program for people with residual disability following hospitalization for COVID-19: Randomized control trial. *Annals of Physical & Rehabilitation Medicine*. 2024;67(2):101815.
17. Sanchez M, Rodriguez S, Martin N, Jimenez L, Ramos H, Campon C, et al. Effects of a respiratory and neurological rehabilitation treatment plan in post COVID-19 affected university students. Randomized clinical study. *Chronic Respiratory Disease*. 2024;21:14799731241255967.
18. Sarmiento A, Adodo R, Hodges G, Webber SC, Sanchez-Ramirez DC. Virtual pulmonary rehabilitation approaches in patients with post COVID syndrome: a pilot study. *BMC Pulmonary Medicine*. 2024;24(1):139.
19. Schmidt F, Azar C, Goektas O. Treatment of olfactory disorders after SARS -COVID 2 virus infection. *Ear, Nose, & Throat Journal*. 2024;103:48S-53S.
20. Slankamenac J, Ranisavljev M, Todorovic N, Ostojic J, Stajer V, Candow DG, et al. Eight-week creatine-glucose supplementation alleviates clinical features of Long COVID. *Journal of Nutritional Science & Vitaminology*. 2024;70(2):174-8.
21. Spiesshoefer J, Regmi B, Senol M, Jorn B, Gorol O, Elfeturi M, et al. Potential diaphragm muscle weakness-related dyspnea persists two years after COVID-19 and could be improved by inspiratory muscle training: results of an observational and an interventional trial. *American Journal of Respiratory & Critical Care Medicine*. 2024;19:19.
22. Tan Y, Xie Y, Dong G, Yin M, Shang Z, Zhou K, et al. The effect of 14-day consumption of hydrogen-rich water alleviates fatigue but does not ameliorate dyspnea in Long-COVID patients: a pilot, single-blind, and randomized, controlled Trial. *Nutrients*. 2024;16(10).
23. Raine G, Khouja C, Harden M, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. Update January 2024. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London; 2024. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.
24. Raine G, Khouja C, Khatwa M, Harden M, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. Update July 2023. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College; 2023. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.
25. Raine G, Khouja C, Khatwa M, Harden M, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. Update April 2023. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London; 2023. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.

26. Raine G, Khouja C, Fulbright H, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. Update April 2024. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London; 2024. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.
27. Raine G, Khouja C, Khatwa M, Harden M, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. Update October 2023. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London 2023. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.
28. Raine G, Khouja C, Khatwa M, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. Update January 2023. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London; 2023. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.
29. Raine G, Khouja C, Harden M, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. Update October 2022. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London; 2022. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.
30. Raine G, Khouja C, Khatwa M, Sutcliffe K, Sowden A. Treatment and rehabilitation of Long COVID: A scope of the literature. London: EPPI Centre, UCL Social Research Institute, UCL Institute of Education, University College London; 2022. Available from: <https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3860>.
31. Barretto Dos Santos Lopes Batista K, Thiruvengkatachari B, O'Brien K. Intention-to-treat analysis: Are we managing dropouts and missing data properly in research on orthodontic treatment? A systematic review. *Am J Orthod Dentofacial Orthop*. 2019;155(1):19-27.e3.
32. Bondemark L, Abdulraheem S. Intention to treat (ITT) analysis as reported in orthodontic randomized controlled trials-evaluations of methodology and recommendations for the accurate use of ITT analysis and handling dropouts. *Eur J Orthod*. 2018;40(4):409-13.
33. Cochrane Australia. Intention-to-treat (ITT) and other forms of data analysis [Video]. 2022 Available from: <https://www.youtube.com/watch?v=mZp2KomA3Ws>.

Appendix 1 – search strategies

Cochrane Controlled Register of Trials (CENTRAL)

via Wiley <http://onlinelibrary.wiley.com/>

Issue: Issue 5 of 12, May 2024

Date searched: 3rd June 2024

Records retrieved: 1624

Although 1624 records were identified overall in CENTRAL, trial register records were removed from this set, leaving a total of 1323 records downloaded for this update.

#1	[mh ^"Post-Acute COVID-19 Syndrome"]	234
#2	[mh ^COVID-19/co]	320
#3	[mh ^COVID-19]	7751
#4	[mh ^SARS-CoV-2]	3228
#5	[mh ^Syndrome]	6616
#6	[mh ^Survivors]	1805
#7	#3 or #4	8009
#8	#5 or #6	8415
#9	#7 and #8	104
#10	#1 or #2 or #9	605
#11	(long next (covid* or "covid-19" or covid19 or coronavirus) or longcovid*):ti,ab,kw	472
#12	(post next (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")) or postcovid*):ti,ab,kw	806
#13	((post next acute or postacute) near/2 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	293
#14	PASC:ti,ab,kw	69
#15	(sequela* near/6 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	177
#16	(chronic near/2 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	43
#17	(ongoing next (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	113
#18	((long* term or longterm) near/3 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	862
#19	(persist* near/6 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	291
#20	((post next discharg* or postdischarg*) near/4 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	17
#21	((long next haul* or longhaul*) near/6 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	16
#22	(surviv* near/3 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	207
#23	(after next (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	340
#24	((ongoing or lasting or prolonged or fluctuat* or residual* or continu* or linger*) near/6 (symptom* or effect* or complication* or sequela* or syndrome or illness* or disorder* or dysfunction* or impair* or impact* or consequence*) near/6 (covid* or "covid-19" or covid19 or coronavirus or "SARS-CoV-2" or "SARS-CoV2" or SARSCoV2 or "SARSCoV-2")):ti,ab,kw	193
#25	{OR #11-#24}	2215
#26	#10 or #25 with Publication Year from 2022 to 2024, in Trials	1517

#27 #10 or #25 with Cochrane Library publication date Between Jan 2022 and Mar 2024, in
Trials 1498
#28 #26 or #27 1624

MEDLINE ALL

(includes: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE)

via Ovid <http://ovidsp.ovid.com/>

Date range: 1946 to May 30, 2024

Date searched: 3rd June 2024

Records retrieved: 1098

The MEDLINE strategy below includes a search filter to limit retrieval to RCTs using the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity and precision-maximizing version (2023 revision); Ovid format.

Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, Noel-Storr A, Rader T, Shokraneh F, Thomas J, Wieland LS. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from: www.training.cochrane.org/handbook.

- 1 Post-Acute COVID-19 Syndrome/ (3413)
- 2 COVID-19 post-intensive care syndrome.mp. (6)
- 3 COVID-19/co (17814)
- 4 COVID-19/ or SARS-CoV-2/ (270941)
- 5 Syndrome/ (124047)
- 6 Survivors/ (31587)
- 7 5 or 6 (155510)
- 8 4 and 7 (1143)
- 9 1 or 2 or 3 or 8 (20394)
- 10 ((long adj (covid\$ or covid-19 or covid19 or coronavirus)) or longcovid\$.ti,ab,kf,ot,bt. (5451)
- 11 ((post adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) or postcovid\$.ti,ab,kf,ot,bt. (11091)
- 12 ((post acute or postacute) adj2 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (1103)
- 13 PASC.ti,ab,kf,ot,bt. (982)
- 14 (sequela\$ adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (3037)
- 15 (chronic adj2 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (361)
- 16 (ongoing adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (3492)
- 17 ((long\$ term or longterm) adj3 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (2556)
- 18 (persist\$ adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (4663)
- 19 ((post discharg\$ or postdischarg\$) adj4 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (97)

- 20 ((long haul\$ or longhaul\$) adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (281)
- 21 (surviv\$ adj3 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (3349)
- 22 (after adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (10404)
- 23 ((ongoing or lasting or prolonged or fluctuat\$ or residual\$ or continu\$ or linger\$) adj6 (symptom\$ or effect\$ or complication\$ or sequela\$ or syndrome or illness\$ or disorder\$ or dysfunction\$ or impair\$ or impact\$ or consequence\$) adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kf,ot,bt. (3225)
- 24 or/10-23 (36728)
- 25 9 or 24 (50460)
- 26 exp randomized controlled trial/ (615611)
- 27 randomized controlled trial.pt. (614044)
- 28 controlled clinical trial.pt. (95541)
- 29 randomi?ed.ab. (772640)
- 30 placebo.ab. (248731)
- 31 clinical trials as topic.sh. (202499)
- 32 randomly.ab. (434508)
- 33 trial.ti. (310251)
- 34 or/26-33 (1652190)
- 35 exp animals/ not humans.sh. (5226717)
- 36 34 not 35 (1524360)
- 37 25 and 36 (1639)
- 38 limit 37 to yr="2022-Current" (1118)
- 39 (2022* or 2023* or 2024*).dt. (3836722)
- 40 37 and 39 (1079)
- 41 38 or 40 (1126)
- 42 preprint.pt. (24563)
- 43 41 not 42 (1112)
- 44 remove duplicates from 43 (1098)

Embase

via Ovid <http://ovidsp.ovid.com/>

Date range: 1974 to 2024 May 31

Date searched: 3rd June 2024

Records retrieved: 1719

The Embase strategy below includes a search filter to limit retrieval to RCTs:

Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of clinical trials published world-wide - the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library. *Emerg Themes Epidemiol* 2008;5:13

- 1 long COVID/ (7741)
- 2 ((long adj (covid\$ or covid-19 or covid19 or coronavirus)) or longcovid\$).ti,ab,kw,ot. (5674)
- 3 ((post adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) or postcovid\$).ti,ab,kw,ot. (14271)
- 4 ((post acute or postacute) adj2 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (1006)
- 5 PASC.ti,ab,kw,ot. (1238)

6 (sequela\$ adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (3797)

7 (chronic adj2 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (470)

8 (ongoing adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (3622)

9 ((long\$ term or longterm) adj3 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (3197)

10 (persist\$ adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (5952)

11 ((post discharg\$ or postdischarg\$) adj4 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (188)

12 ((long haul\$ or longhaul\$) adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (303)

13 (surviv\$ adj3 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (4915)

14 (after adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (14164)

15 ((ongoing or lasting or prolonged or fluctuat\$ or residual\$ or continu\$ or linger\$) adj6 (symptom\$ or effect\$ or complication\$ or sequela\$ or syndrome or illness\$ or disorder\$ or dysfunction\$ or impair\$ or impact\$ or consequence\$) adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,kw,ot. (3975)

16 or/2-15 (46619)

17 1 or 16 (47363)

18 random\$.ti,ab. (2074920)

19 factorial\$.ti,ab. (49513)

20 crossover\$.ti,ab. (93967)

21 cross-over\$.ti,ab. (38838)

22 placebo\$.ti,ab. (380097)

23 (doubl\$ adj blind\$).ti,ab. (252616)

24 (singl\$ adj blind\$).ti,ab. (33235)

25 assign\$.ti,ab. (513836)

26 allocat\$.ti,ab. (214324)

27 volunteer\$.ti,ab. (303164)

28 Crossover Procedure/ (78221)

29 double blind procedure/ (219652)

30 Randomized Controlled Trial/ (824645)

31 single blind procedure/ (54978)

32 controlled clinical trial/ (473278)

33 or/18-32 (3201959)

34 (animal/ or animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/ (6999489)

35 33 not 34 (2859089)

36 17 and 35 (3145)

37 limit 36 to yr="2022 -Current" (2326)

38 (2022\$ or 2023\$ or 2024\$).dd. (1503749)

39 36 and 38 (842)

40 37 or 39 (2447)

41 (conference abstract or "conference review").pt. (5186136)

42 40 not 41 (1844)

43 limit 42 to "remove preprint records" (1719)

PsycINFO

via Ovid <http://ovidsp.ovid.com/>

Date range: 1806 to May Week 5 2024

Date searched: 5th June 2024

Records retrieved: 465

The PsycINFO strategy below includes a search filter to limit retrieval to RCTs developed by the information specialist at the Cochrane Common Mental Disorders Group.

- 1 post-covid-19 conditions/ (226)
- 2 covid-19/ (36179)
- 3 coronavirus/ (6086)
- 4 syndromes/ (18215)
- 5 sequelae/ (4049)
- 6 2 or 3 (38639)
- 7 4 or 5 (22195)
- 8 6 and 7 (364)
- 9 1 or 8 (557)
- 10 ((long adj (covid\$ or covid-19 or covid19 or coronavirus)) or longcovid\$.ti,ab,id,ot. (347)
- 11 ((post adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) or postcovid\$.ti,ab,id,ot. (1174)
- 12 ((post acute or postacute) adj2 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (59)
- 13 PASC.ti,ab,id,ot. (61)
- 14 (sequela\$ adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (237)
- 15 (chronic adj2 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (26)
- 16 (ongoing adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (399)
- 17 ((long\$ term or longterm) adj3 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (221)
- 18 (persist\$ adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (325)
- 19 ((post discharg\$ or postdischarg\$) adj4 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (7)
- 20 ((long haul\$ or longhaul\$) adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (24)
- 21 (surviv\$ adj3 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (343)
- 22 (after adj (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (644)
- 23 ((ongoing or lasting or prolonged or fluctuat\$ or residual\$ or continu\$ or linger\$) adj6 (symptom\$ or effect\$ or complication\$ or sequela\$ or syndrome or illness\$ or disorder\$ or dysfunction\$ or impair\$ or impact\$ or consequence\$) adj6 (covid\$ or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)).ti,ab,id,ot. (385)
- 24 or/10-23 (3235)
- 25 Randomized Clinical Trials/ (556)
- 26 randomized controlled trials/ (1075)

- 27 clinical trials/ (12359)
- 28 clinical trial.md. (42470)
- 29 (randomi#ed or randomi#ation or randomi#ing).ti,ab,id. (115884)
- 30 randomly.ti,ab,id. (87054)
- 31 (RCT or "at random" or (random* adj3 (administ* or allocat* or assign* or class* or cluster* or control* or crossover or cross over or pragmatic or quasi or determine* or divide* or division or distribut* or expose* or fashion or number* or place* or recruit* or split or substitut* or treat*))).ti,ab,id. (135661)
- 32 (groups or (control* adj3 group*)).ab. (634113)
- 33 ((control* or trial or study or group*) and (waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,id,hw. (20154)
- 34 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,id. (30039)
- 35 trial.ti. (40687)
- 36 (placebo or sham).ti,ab,id,hw. (59936)
- 37 treatment outcome.md. (24978)
- 38 treatment effectiveness evaluation/ (29762)
- 39 mental health program evaluation/ (2495)
- 40 or/25-39 (842343)
- 41 9 or 24 (3411)
- 42 40 and 41 (538)
- 43 limit 42 to yr="2022 -Current" (398)
- 44 (2022\$ or 2023\$ or 2024\$).up. (464765)
- 45 42 and 44 (454)
- 46 43 or 45 (466)
- 47 remove duplicates from 46 (465)

CINAHL Ultimate

via Ebsco <https://www.ebsco.com/>

Date range: Inception to 20241231

Date searched: 3rd June 2024

Records retrieved: 898

The CINAHL strategy below includes a search filter to limit retrieval to RCTs developed by Glanville et al.:

Glanville J, Dooley G, Wisniewski S, Foxlee R, Noel-Storr A. Development of a search filter to identify reports of controlled clinical trials within CINAHL Plus. *Health Info Libr J* 2019;36:73-90.

- S1 (MH "Post-Acute COVID-19 Syndrome") (1,375)
- S2 TI (long N1 (covid* or covid-19 or covid19 or coronavirus) or longcovid*) OR AB (long N1 (covid* or covid-19 or covid19 or coronavirus) or longcovid*) (1,654)
- S3 TI (post N1 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2) or postcovid*) OR AB (post N1 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2) or postcovid*) (1,844)
- S4 TI (("post acute" or post-acute or postacute) N3 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB (("post acute" or post-acute or postacute) N3 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (394)
- S5 TI PASC OR AB PASC (119)

- S6 TI (sequela* N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB (sequela* N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (646)
- S7 TI (chronic N2 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB (chronic N2 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (291)
- S8 TI (ongoing N1 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB (ongoing N1 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (742)
- S9 TI ((long* N1 term or long-term or longterm) N3 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB ((long* N1 term or long-term or longterm) N3 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (1,146)
- S10 TI (persist* N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB (persist* N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (1,036)
- S11 TI ((post N1 discharg* or post-discharg* or postdischarg*) N4 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB ((post N1 discharg* or post-discharg* or postdischarg*) N4 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (51)
- S12 TI ((long N1 haul* or long-haul* or longhaul*) N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB ((long N1 haul* or long-haul* or longhaul*) N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (90)
- S13 TI (surviv* N3 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB (surviv* N3 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (1,127)
- S14 TI (after N1 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB (after N1 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (4,606)
- S15 TI ((ongoing or lasting or prolonged or fluctuat* or residual* or continu* or linger*) N6 (symptom* or effect* or complication* or sequela* or syndrome or illness* or disorder\$ or dysfunction* or impair* or impact* or consequence*) N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) OR AB ((ongoing or lasting or prolonged or fluctuat* or residual* or continu* or linger*) N6 (symptom* or effect* or complication* or sequela* or syndrome or illness* or disorder\$ or dysfunction* or impair* or impact* or consequence*) N6 (covid* or covid-19 or covid19 or coronavirus or SARS-CoV-2 or SARS-CoV2 or SARSCoV2 or SARSCoV-2)) (960)
- S16 (MH "Randomized Controlled Trials+") (145,077)
- S17 (MH "Double-Blind Studies") (54,356)
- S18 (MH "Single-Blind Studies") (16,110)
- S19 (MH "Random Assignment") (85,617)
- S20 (MH "Pretest-Posttest Design") (56,469)
- S21 (MH "Cluster Sample") (5,604)
- S22 TI randomised OR randomized (336,176)
- S23 AB random* (404,285)
- S24 TI trial (194,929)
- S25 MH (sample size) AND AB (assigned OR allocated OR control) (4,499)
- S26 MH (placebos) (14,455)
- S27 PT (randomized controlled trial) (157,346)

S28 AB (control W5 group) (149,479)
S29 MH (crossover design) OR MH (comparative studies) (503,294)
S30 AB (cluster W3 RCT) (509)
S31 MH animals+ (102,413)
S32 MH (animal studies) (156,706)
S33 TI (animal model*) (3,957)
S34 S31 OR S32 OR S33 (250,134)
S35 MH (human) (2,807,550)
S36 S34 NOT S35 (215,464)
S37 S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 (1,059,698)
S38 S37 NOT S36 (1,010,880)
S39 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
OR S14 OR S15 (12,104)
S40 S38 AND S39 (1,222)
S41 S38 AND S39 Limiters - Publication Date: 20220101-20241231 (881)
S42 (ZD 2022* or 2023* or 2024*) (362,127)
S43 S40 AND S42 (268)
S44 S41 OR S43 (898)

Appendix 2

The Joanna Briggs Institute Critical Appraisal Checklist for Randomized Controlled Trials

Q1 Was true randomization used for assignment of participants to treatment groups? Yes, No, Unclear, NA

Q2 Was allocation to treatment groups concealed? Yes, No, Unclear, NA

Q3 Were treatment groups similar at the baseline? Yes, No, Unclear, NA

Q4 Were participants blind to treatment assignment? Yes, No, Unclear, NA

Q5 Were those delivering treatment blind to treatment assignment? Yes, No, Unclear, NA

Q6 Were outcomes assessors blind to treatment assignment? Yes, No, Unclear, NA

Q7 Were treatment groups treated identically other than the intervention of interest? Yes, No, Unclear, NA

Q8 Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed? Yes, No, Unclear, NA

Q9 Were participants analyzed in the groups to which they were randomized? Yes, No, Unclear, NA


Q10 Were outcomes measured in the same way for treatment groups? Yes, No, Unclear, NA

Q11 Were outcomes measured in a reliable way? Yes, No, Unclear, NA

Q12 Was appropriate statistical analysis used? Yes, No, Unclear, NA

Q13 Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial? Yes, No, Unclear, NA

Appendix 3: Flow of studies through the review



The NIHR Policy Research Programme Reviews Facility aims to put the evidence into development and implementation of health policy through:

- Undertaking policy-relevant systematic reviews of health and social care research
- Developing capacity for undertaking and using reviews
- Producing new and improved methods for undertaking reviews
- Promoting global awareness and use of systematic reviews in decision-making

The Reviews Facility is a collaboration between the following centres:
EPPI Centre (Evidence for Policy and Practice Information Centre),
UCL Institute of Education, University College London;
CRD (Centre for Reviews and Dissemination), University of York;
and the London School of Hygiene and Tropical Medicine.

The NIHR Policy Research Programme Reviews Facility collaboration has grown out of a previous 'reviews facility' in Health Promotion and Public Health based at the EPPI Centre, and has been funded by the Department of Health and Social Care since 1995.

The views expressed in this work are those of the authors and do not necessarily reflect the views of the collaborating centres or the funder. All errors and omissions remain those of the authors.

First produced in 2024 by:

Evidence for Policy and Practice Information Centre (EPPI Centre)
Social Science Research Unit, UCL Social Research Institute
UCL Institute of Education, University College London
18 Woburn Square
London WC1H 0NR

<http://eppi.ioe.ac.uk>
<http://www.ucl.ac.uk/ioe>

This document is available in a range of accessible formats including large print. Please contact the Social Science Research Unit for assistance.

Email: ioe.ssru@ucl.ac.uk
Telephone: +44 (0)20 7331 5263